CONSORT diagram: NSABP Protocols B-30, B-31, B-34, and B-38. BC

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Cancers, Free Full-Text

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01

A population-based study on the patterns of use of different chemotherapy regimens in patients with early breast cancer

Landmark trials in breast cancer.pptx

Overestimation of Late Distant Recurrences in High-Risk Patients

Cancers, Free Full-Text

Joseph P Costantino's research works

Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

Frontiers Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II